CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case

Abstract

Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2 (HER2). In this clinical observation, analysis of the effectiveness of treatment of a patient with metastatic breast cancer of luminal A subtype is performed. The 1st line combination therapy was CDK4/6 inhibitors (ribociclib) and hormone therapy with aromatase inhibitors (letrozole) and analogues of gonadotropin-releasing hormone (goserelin) with concurrent bone-modifying denosumab therapy. Effectiveness of antitumor drug therapy administered for 7 months, and toxicity of the regimen were evaluated. Effectiveness of the selected combination treatment regimen was demonstrated and confirmed by clinical data, as well as results of laboratory and instrumental examinations. Adverse effects were controlled and managed with symptomatic therapy which allows to continue treatment using previously selected tactics.